Article
Reference
Triple Network Model Dynamically Revisited: Lower Salience Network State Switching in Pre-psychosis
BOLTON, Thomas A. W., et al.
Abstract
Emerging evidence has attributed altered network coordination between the default mode, central executive, and salience networks (DMN/CEN/SAL) to disturbances seen in schizophrenia, but little is known for at-risk psychosis stages. Moreover, pinpointing impairments in specific network-to-network interactions, although essential to resolve possibly distinct harbingers of conversion to clinically diagnosed schizophrenia, remains particularly challenging. We addressed this by a dynamic approach to functional connectivity, where right anterior insula brain interactions were examined through co-activation pattern (CAP) analysis.
We utilized resting-state fMRI in 19 subjects suffering from subthreshold delusions and hallucinations (UHR), 28 at-risk for psychosis with basic symptoms describing only self-experienced subclinical disturbances (BS), and 29 healthy controls (CTR) matched for age, gender, handedness, and intelligence. We extracted the most recurring CAPs, compared their relative occurrence and average dwell time to probe their temporal expression, and quantified occurrence balance to assess the putative loss of [...]
BOLTON, Thomas A. W., et al . Triple Network Model Dynamically Revisited: Lower Salience Network State Switching in Pre-psychosis. Frontiers in Physiology , 2020, vol. 11, p. 66
DOI : 10.3389/fphys.2020.00066 PMID : 32116776
Available at:
http://archive-ouverte.unige.ch/unige:155724
Disclaimer: layout of this document may differ from the published version.
1 / 1
Supplementary Material
SUPPLEMENTARY TABLES
Index Group Antipsychotic (Dose [mg]) Antidepressant (Dose [mg]) Exclusion criteria
E128 UHR Sertralin (50), Trittico (150)
E129 UHR
E130 BS Seroquel (100), Temesta (1) E131 UHR Seroquel (300), Cipralex (10)
E132 BS
E133 BS
E134 BS Trittico (100)
E136 BS
E137 UHR Fluoxetine (100)
E140 BS
E143 BS
E144 BS
E146 BS
E147 UHR Invega (3)
E149 BS
E150 BS Relaxane intake
E151 BS Seroquel XR (50), Cipralex (20)
E154 BS Seroquel (25)
E155 UHR
E156 BS Zoloft (75), Deroxat (100)
E157 BS Seroquel (25) Trittico (50) Excessive motion
E159 UHR
E161 UHR
E163 BS Zoloft (75)
E165 BS Seroquel XR (50) Effexor (225)
E166 UHR
E167 UHR
E170 BS
E173 UHR
E175 UHR Risperdal (0.25)
E176 BS
E177 UHR
E178 BS
E179 BS
E180 UHR Abilify (10)
E181 UHR
E182 UHR
E183 BS
E184 BS
E186 BS Excessive motion
E189 BS
E191 BS
E192 BS
1
Supplementary Material
E196 UHR Fluctin (20)
E197 UHR
E198 UHR Excessive motion
E199 BS
K006B CTR
K015 CTR
K017 CTR
K020 CTR
K021 CTR
K022 CTR
K024 CTR
K027 CTR
K029 CTR
K030 CTR
K033 CTR
K034 CTR
K036 CTR
K037 CTR
K038 CTR
K042 CTR
K043 CTR
K044 CTR
K045 CTR
K047 CTR
K048 CTR
K049 CTR
KJ001 CTR KJ002 CTR KJ005 CTR KJ010 CTR KJ016 CTR KJ017 CTR KJ018 CTR
Table S1: List of all 76 subjects initially considered in this work, with details regarding the taken antipsychotic drugs and antidepressants, as well as exclusion criteria whenever applicable. Three subjects (2 BS, 1 UHR) were excluded because of excessive motion (more than 20%
of frames scrubbed out), and one BS subject was excluded due to the intake of relaxane prior to scanning, resulting in outlier values for the assessed metrics. Other medications not listed in the table include Focalin (E154), Ritalin (E154, E156, E196), Temesta (E170), Strattera (E175), and Redormin (E180). CTR: healthy controls. BS: subjects with basic symptoms of psychosis. UHR: subjects at ultra-high risk for psychosis.
2
